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This thesis presents a foundation for developing a business case for companies 
interested in the reconstructive and cosmetic procedure markets.  The focus is on 
reviewing adipose tissue engineering research and proposing technology opportunities 
that could be applied to challenging soft tissue reconstruction cases and adjacently 
applied to cosmetic applications.  To establish the foundation for this type of program, 
this thesis includes an evaluation of the reconstructive and cosmetic procedure markets, 
current practices in these markets and their constraints, as well as a literature review of 
research in adipose tissue engineering and its potential clinical applications.  Additionally 
it captures the competitive landscape of major players in the reconstructive market as 
well as up-and-coming players in the adipose tissue engineering field.  Technology 
development opportunities with associated customer and business value are discussed 
with a recommendation for the development of a detailed business case to evaluate 
specific product development opportunities in these markets. 
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 Reconstructive surgery is a $1 billion market fraught with unmet needs due to 
large numbers of people in the world presenting a vast array of clinical challenges.  This 
market includes patients with a wide-range of medical issues including a great deal of 
variance in affliction sites, causes and severity of injuries, age of patients, and many other 
complications.  The commonality in the market is generally the affliction to body contour 
and deficits in soft tissue, therefore treatment options and products available for 
reconstruction are often those developed for the cosmetic surgery market, estimated at 
$30 billion annually.  Reconstructive treatment options should be adaptable to the varied 
circumstances and intervention requirements.  However, for most patients this is not the 
case. 
 Though available market analyses focus on current treatment options, their 
growth potential, and advice for new entrants into the market, they do not provide a 
thorough evaluation of true market, patient-driven needs.  This requires an assessment of 
the unmet needs of the population for which the market covers.  To do this, the 
constraints of current options must be assessed and potential technological developments 
evaluated for their ability to address gaps in the market.     
 Reconstruction is critical in patients with soft tissue defects (Figure 1) due to 
cancer, trauma, deep burns, and congenital abnormalities.  Viable options for these 
patients are lacking and in many circumstances aren’t available for specific deficits.  
Current procedures include the use of synthetic and natural implant materials, tissue-flap 
grafting, and small volume fat grafting, all of which have drawbacks.  Optimizing fat 
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grafting, which uses autologous adipose tissue for reconstruction of soft tissue deficits, is 
a growing area of technology research which has the potential to expand treatment 
options and open new markets.  
 
Figure 1: Depiction of a Soft Tissue Defect. Adapted from [4]. 
 Synthetic and natural materials are used to fill the tissue-deficits; however, they 
do not restore function and cannot be used in all soft tissue reconstruction applications.  
Additionally, these materials can cause allergic reactions, side effects, infection, and 
fibrous tissue formation.  Though there have been advances in materials development, 
there are still many problems associated with their clinical efficacy. 
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Another contemporary practice for the reconstruction of soft tissue deficits is flap 
grafting.  This procedure uses a section of the patient’s skin, fat, and muscle from a donor 
site, typically the abdomen, thigh, buttocks, or back, and grafts it in the area of the soft 
tissue deficit using  microsurgical techniques (Figure 2).  These highly specialized 
techniques are very costly in both time and money and require microvascular-surgeons.  
Availability and reimbursement for this type of reconstruction is rare. Additionally, the 
flap donor site is left with a deficit and usually a loss of function due to the removal of 
muscle. While this procedure eliminates some of the pit-falls of implantable materials by 
using a patient’s own tissue, it has significant drawbacks. 
      
Figure 2:  Flap graft illustration for breast reconstruction. 
 Clinics are evaluating the use of fat grafting alone or in combination with 
implantable materials for reconstructive and cosmetic surgeries [1, 2].  These techniques 
use a patient’s own fat tissue to fill soft tissue deficits and therefore avoid most of the 
problems associated with synthetic and natural material implants.  Additionally, this 
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process can be applied to a wide variety of soft tissue defects with various shapes and 
volume deficits.  The most common process uses adipose tissue obtained from 
liposuction that is then injected into the recipient site during several procedures, generally 
two to five, to make up for the 40-60% graft volume loss after each procedure [2].  This 
volume loss has been attributed to the lack of vascularization, or vessel in-growth, into 
the grafted tissue.  Only small volumes can be maintained by the surrounding vessels 
because fat cells require immediate nutrition (within hours) from the blood supply to 
survive [3].  Therefore, this limitation will have to be overcome to make fat grafting a 
leading option in soft tissue reconstruction.  
There are patients with soft tissue deficits that do not have appropriate treatment 
options due to the limitations of current practices in reconstructive procedures described 
above.  Patients undergoing lumpectomies, a partial removal of the breast, or extremity 
tumor resections (Figure 3,left) are not ideal candidates for implants or flap grafts.  For 
example, the 18 year old female, shown in Figure 3, right, was born with Poland’s 
Syndrome, a congenital defect that prevents normal development of the pectoral muscle 
and associated soft tissue of the chest.  Due to the tissue deficit of the chest muscle, an 
implant would not result in an ideal symmetrical cosmetic outcome.   Therefore these 
types of patients require new, clinically practical technologies to address their needs. 
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Figure 3: Left – 38 year old female 34 years after radiation treatment of a tumor. Adapted 
from [1].  Right – 18 year-old female with Poland’s Syndrome. Adapted from [2]. 
 
Adipose tissue is an ideal material for soft tissue augmentation.  It is ubiquitous in 
the human body, is the most abundant tissue, and is generally in excess within the patient 
[4].  Adipose tissue is inexpensive, readily available, easy to acquire, lacks an 
inflammatory or immune response, and lacks late appearing side effects or complications 
[5].  However, its clinical use as a graft is fraught with problems and limitations.  The 
graft is not long lasting once transplanted and the results are varied and hard to predict.  It 
is unknown how to overcome the onerous time, cost, and technique dependence 
requirements of fat grafting.  Therefore, much work must be done to turn this ideal 
material into a practical, clinically usable solution.   
The field of tissue engineering emerged to address limitations using autologous 
tissues for the treatment of a variety of medical conditions.  This field is generally 
recognized for advances in combining cells, biomaterial scaffolds, and modulated 
microenvironments into fabricated grafts that mimic natural physiology of the tissue it is 
replacing [6].  Adipose tissue engineering, a subset of the field, emerged specifically to 
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address limitations in soft tissue reconstruction by applying the principles of tissue 
engineering to adipose tissue.  It has been expressed that “the employment of natural 
biology of the system will allow for greater success in developing therapeutic strategies” 
[7].  Therefore, it is important to not only understand the potential for creating entirely in 
vitro fabricated adipose grafts, but also the stimulation of the in vivo local environment 
such that new adipose tissue can form without the use of exogenous cells [8].  Though fat 
grafting, as currently practiced, is not adipose tissue engineering in the classical sense, 
manipulation of the microenvironment in addition to adipose tissue or adipose-derived 
stem cells with or without biomaterials are each described as adipose tissue engineering 
strategies.  Therefore, broad research to understand adipose biology and tissue 
engineering applications to use, modify, and grow adipose tissue for reconstructive and 
cosmetic applications is ongoing and rapidly expanding. 
Several important unmet needs must be addressed to successfully create a 
clinically practical adipose tissue engineering technology.  Advances must be made to 
facilitate preparation of the transplant-recipient site to accept and incorporate large 
volume grafts, an endeavor that clearly falls outside the classic tissue engineering 
definition.  Subsequent graft preparation and maintenance to prevent necrosis, or cell 
death, due to lack of vascularization and nutrient supply is also a major area of concern.  
If the technology incorporates the use of harvested fat or adipose-derived stem cells, 
harvesting and storage procedures needs to be optimized due to the labile nature of 
adipose tissue.  Significant cell damage can lead to low graft take and side effects, such 
as cyst formation when adipose tissue is not handled or prepared properly.  
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Understanding how to handle, prepare, and enhance vascularization of adipose tissue 
before and after transplantation will significantly impact success.   
To fulfill the potential for the application of adipose tissue engineering in 
reconstructive surgery, it is important to fully understand where it fits in the current 
market.  An assessment of market drivers and constraints will provide information about 
current unmet needs and how they could be addressed by the introduction of adipose 
technologies as clinically applicable solutions.  Additionally, these technologies could 
then be adjacently applied to the cosmetic procedure market to address additional unmet 
needs and growing constraints.  Market dynamics, potential opportunities, and new 
technologies are inter-related and need to be evaluated and pursued as a focused and 
integrated program of developing innovative technologies for the reconstructive and 





Reconstructive surgery refers to surgical procedures to restore the appearance and 
function of a damaged part of the body.  This market currently includes breast 
reconstruction, mainly in the area of mastectomies and repair of congenital defects, 
extremity reconstruction related to trauma, wound defects, tumor resection, and facial 
reconstructive surgeries.  The current global reconstructive market is estimated to exceed 
$1 billion annually.  Additionally, the market for reconstructive surgery is predicted to 
grow and in the case of Europe, market growth is accelerating (Figure 4).   
 
 
Compound Annual Growth Rate (2006-2013): 5.0% 




During 2009, nearly 5 million reconstructive procedures were performed in the 
United States, over 3.5 million of which were due to tumor removal, up 5% from 2008.  
These procedures are frequently intended to restore aesthetics or reconstruct natural 
appearance and feel [10].  The following table includes the top five reconstructive 
procedures according to the 2009 statistics in the American Society of Plastic Surgeons 
(ASPS) 2010 Report [11]: 
Procedure Number of Procedures 
Tumor Removal 3,900,000 
Laceration Repair 332,000 
Scar Revision 171,000 
Hand Surgery 110,000 
Maxillofacial 
Surgery 90,000 
Table 1: 2009 Statistics of Reconstructive Surgeries [11]. 
   
Breast and extremity reconstruction post tumor removal are large reconstruction 
markets.  A Frost & Sullivan report on the Reconstructive Surgery Market in Europe 
states that breast and extremities reconstruction markets are experiencing small to 
moderate growth.  There are many market drivers responsible for the growth.  However, 
there are also several market constraints, primarily based on the current technologies 
available to the market.  Therefore, if there were more options in the reconstructive 
market, such as clinically practical adipose tissue engineering technology, additional 




The high incidence of breast cancer is a prominent driver for the breast 
reconstruction market (Figure 5).  Currently there are over 5 million breast cancer 
survivors world-wide [9].  These women typically undergo mastectomies or 
lumpectomies as part of their treatment causing either a total or partial loss of the breast.  
The psychological impact from the change in appearance of the patient’s body is a large 
driver for reconstructive surgery.  Insurance companies traditionally have considered 
breast reconstruction an elective cosmetic procedure.  However, today there is an 
increasing trend toward reimbursement making reconstruction more available to those 
who need it after cancer treatment. 
 
Figure 5:  Breast Reconstruction Market Drivers.  Adapted from [9]. 
There has also been an increase in early detection facilitated by new technologies, 
public education, and better access to screening thanks to new congressional laws.  As a 
result, nearly 60% of patients will choose a lumpectomy procedure over a mastectomy 
[9].  Currently, this is considered a constraint on the market because the available 
reconstructive options are largely limited to whole breast saline or silicone implants.  It is 
difficult to treat the wide variety of soft tissue deficits resulting from lumpectomy 
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procedures and as a result there are very few reconstructive options for these patients.  
However, this need could turn into a very large market driver for adipose tissue grafting. 
 
Figure 6:  Breast Reconstruction Market Constraints.  Adapted from [9]. 
 Another constraint on the current reconstructive market is the perception that 
cancer might not be detected if the area is reconstructed, particularly where synthetic 
materials and implants are used (Figure 6).  It is thought that implants could hide 
suspicious lesions or rupture during screening [9]. However, if fat grafting were a viable 
option for reconstruction after tumor removal, it may modulate some of these fears.  The 
grafted tissue would be from the patient’s body and incorporate into the tissue of the 
affected area, unlike implants.  This could make the patient feel more comfortable with 
future cancer screening.  Therefore, though this is a constraint for the current 
reconstructive market, it could be a driver for a market that included viable fat grafting or 
tissue engineering options. 
There are other market restraints for breast reconstruction, which perhaps could 
apply to reconstruction in general.  Reconstructive surgeons are increasingly moving 
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toward cosmetic procedures due to the financial benefit associated with the private payer 
cosmetic procedure market.  This is a difficult issue that will have to be addressed by 
government, society, and insurance companies.  Additionally, there is often limited 
access to reconstructive options in general due to the shortage of reconstructive surgeons, 
lack of all-inclusive health insurance, and sometimes even the patient’s location. 
Extremity Reconstruction 
Extremity reconstruction is a large area of the market that could be significantly 
impacted by advancements in adipose tissue engineering and fat grafting.  The types of 
soft tissue deficits in the extremities are similar to lumpectomy patients in that they do 
not have many reconstructive options, particularly options with good cosmetic outcomes.  
Therefore, this is not only a growing market, but one with the potential for even larger 
growth should adipose tissue engineering produce widely available technologies.   
There are many factors driving the extremity reconstruction market (Figure 7).  
One of the most significant includes increased life expectancy.  With advanced age 
comes increased risk of diabetes, arthritis, and cancer, all of which contribute to soft 
tissue deficits in the extremities.  Bone cancer, particularly in young adults, is being 
treated with conservative procedures sparing whole extremity amputations and creating a 
greater need for reconstruction.  Similarly, casualties in the Iraq and Afghanistan wars 
have contributed significantly to this market.  Again, conservative procedures are being 
practiced where possible, creating more need for reconstruction of damaged extremities.  
Additionally, there has been an increase in sports-related injuries worldwide leading to 
the need for reconstructive surgery, particularly in the younger generations [9].  All of 
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these health related contributors increase not only the need for reconstruction, but also for 
advancements in the market to fully address both functional reconstruction and 
appearance. 
 
Figure 7:  Extremity Reconstruction Market Drivers.  Adapted from [9]. 
Continued innovation and introduction of new technologies and materials is also 
driving the reconstructive surgery market.  Though there has been much research 
evaluating biocompatible and biomimetic materials for use in reconstruction, there are 
unmet needs in this area as described previously.  This major driver could especially be 
impacted by new developments and innovation in the area of adipose tissue grafting. 
Though the market is growing and there are a number of drivers, there are still 
some constraints on the market (Figure 8).  Namely, reimbursement for extremity 
reconstructive surgery is not widely available as it is viewed as cosmetic, particularly 
when appearance is primarily affected.  The large thigh defect depicted in Figure 3 is a 
classic example.  Additionally, advances in car design, such as airbags and seatbelts, have 




Figure 8:  Extremity Reconstruction Market Constraints.  Adapted from [9]. 
 In summary, the reconstructive surgery market is growing and has significant 
potential for increased growth if current unmet needs are addressed.  Adipose tissue 
engineering has the potential to greatly impact and augment this market.  Though there 
are several constraints, there are an even greater number of opportunities for technology 
development and market innovation. 
Cosmetic Surgery 
 The reconstructive surgery market is closely linked to the cosmetic surgery 
market.  Whereas reconstruction is done to repair the appearance or function of a deficit, 
cosmetic surgery uses similar procedures purely to alter or enhance the body.  The global 
cosmetic procedure market is estimated to be $30 billion annually with a compound 
annual growth rate of 25% [12].  This growth rate can be attributed to not only health 
issues related to increased life expectancy, but also to societal pressures and the desire to 
look young.  Additionally, the expense of these procedures is borne solely by the patient 
as insurance reimbursement is not available.  Because the cosmetic and reconstructive 
markets rely mainly on similar procedures, technologies, and materials, any new 
technology developed using adipose tissue engineering would impact both markets.  For 
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these reasons, the cosmetic surgery market is a very attractive market offers sustentative 
growth opportunity in addition to reconstruction. 
 According to the American Society for Aesthetic Plastic Surgery (ASPS) 2006 
statistics, during 2006, there were 11.5 million cosmetic procedures performed.  Almost 2 
million of these were considered surgical procedures, while the remaining 9.5 million 
were classified as non-surgical, including Botox and wrinkle filling.  A list of common 
cosmetic procedures performed that could be impacted by the development of a clinically 
relevant tissue engineering process can be found in Table 2 below.  This table also breaks 
down the market size by procedure and total expenditures in the United States. 
Procedure Number of Procedures 
Total Annual 
Expenditure 
Breast Augmentation 383,886 $ 10.4 Billion 
Buttock Augmentation 2,556 $ 12 Million 
Cheek Implants 18,920 $ 13 Million 
Liposuction 403,684 $  956 Million 
Soft Tissue Fillers 
1. Autologous Fat 





$ 140 Million 
$ 1.1 Billion 
Table 2:  Cosmetic procedures with potential to benefit from an innovation in autologous 
fat grafting.  2006 US statistics [12]. 
 Like any market, there are both drivers and constraints in the cosmetic surgery 
market.  However, from the predicted growth of 25% annually, it is obvious that there are 
many more market drivers.  These drivers can be further categorized by their impact on 




Figure 9:  Cosmetic Procedures Market Drivers and Restraints [13]. 
Low impact market drivers include the increase in the aging population, changes 
in practitioner economics, and the fact that cosmetic procedures can now be financed.  As 
mentioned previously, the societal drive to maintain looking young and healthy has a 
significant impact as life expectancy increases and people are more active at an older age.  
Plastic surgeons are increasingly choosing to focus on cosmetic procedures instead of 
reconstructive.  This allows practitioners more flexibility for charging customers, making 
use of payment plans and credit lines.  This availability and flexibility makes a market 
that once only catered to high society much more available to the general public.  
Societal changes have added significant market drivers as well.  There is an 
increase in disposable income and better acceptance of cosmetic procedures.  This can be 
largely attributed to the role of media and advertising glamorizing cosmetic 
augmentation.  This coverage has made this market part of everyday life, which drives 
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more people, who once may have thought it taboo, to feel more comfortable getting 
cosmetic work.  
One of the most significant drivers for the cosmetic market is the development of 
less invasive procedures with good cosmetic outcome.  This can explain the wide 
adoption of Botox over wrinkle fillers in the past few years.  Therefore, new entrants in 
the market must consider invasiveness of the procedure thoroughly when developing new 
technologies.  Acceptance of new procedures or technologies will be significantly 
impacted by this driver and therefore if they require invasive procedures (i.e. surgical), 
the cosmetic result must be perceived as having better results than anything else on the 
market.  
The constraints on the market are mainly procedurally related and include lack of 
pre-treatment information, potential risk of infection, and fears about long term effects.  
These issues could be addressed by the introduction of adipose tissue grafting as a viable 
option, particularly reducing fears of long term effects since it uses a patient’s own tissue.  
Pre-treatment information and risk of infection must be addressed by the practitioners in 
relation to the specific procedures.  However, technology innovation and clear marketing 
strategies could help alleviate these constraints as well. 
The most significant constraint is the competitive nature of the cosmetic 
procedure market.  Several major players dominate the market with high volumes, so 
pricing constraints are not as great an issue for them.  However, to enter the cosmetic 
market the pricing must still be competitive, yet pricing strategy with lower initial market 
penetration must be carefully planned to make a successful entrance.  Therefore, due to 
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the competitive nature of the industry for new entrants, it would be best to fully develop 
and characterize new technologies within a different market, such as reconstruction.  This 




TECHNOLOGY LITERATURE REVIEW 
Current Clinical Practice 
Methods currently used for soft tissue deficit reconstruction include 
transplantation of whole tissue flaps, implants or injection of fillers, and fat grafting.  The 
choice to use one over the other is dependent on several factors, including severity of the 
defect, cost of the procedure, and access to the appropriate experts.  Table 3 lists 
advantages and disadvantages of each treatment.   
Current Strategy Advantages Disadvantages 
Autologous Flaps 
          Free Flaps Autologous sources reduce host  
     immune response 
Increased biocompatibility 
Transplant Efficiency 
Micro-surgery is time   
intensive & costly 
        Perforator Flaps  Long-term stability 
  Donor-site morbidity  
Commercially Available Materials 
         Decelularized Tissue      
          (ECM/Tissue Components)           
Act as filler for soft tissue defects 
Provide short-term solution 
Mechanical integrity 
Fibrous capsule contraction 
        Minerals/Vegetable oils  Volume loss with time 
        Paraffin   
        Synthetic polymers   
        Silicone   
   Fat grafting   
        Autologous source reduces host  
     immune response 
Volume Loss with time 
 No donor-site morbidity Requires multiple sessions 
  Generally plentiful tissue 
Less invasive surgery 
 
  
Table 3: Current Practices in Soft Tissue Reconstruction.  Adapted from [14]. 
Autologous Flaps 
Difficulties in primary closure of large defects, especially immediately following 
large tumor resections, can be overcome by reconstruction using vascularized tissue 
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transplantation, also known as autologous flap grafting [15].  The use of whole-tissue 
flaps requires microvascular surgery to reconnect the blood supply from the surrounding 
tissue with the graft.  This prevents the interruption of blood flow and thus results in a 
relatively stable volume transplant.  The fact that the tissue is moved from one place on a 
person’s body to reconstruct the defect increases its biocompatibility and generally 
restores both volume and function. 
 There are two types of flap procedures; free tissue and perforator (or pendulum) 
flaps.  Free flaps are full thickness tissue grafts taken from one area of the body, 
completely disconnected, and transplanted to the defect site.  Perforator flaps, on the 
other hand, preserve vascularization and nerve connections by harvesting only skin and 
subcutaneous fat while the underlying muscle is split, leaving a pendulum-like 
connection when rotated [16].  The main advantage of perforator flaps is the reduction of 
donor morbidity because part of the vasculature and nerve system remains connected 
[16].  However, local perforator flaps sometimes do not provide adequate coverage, 
especially when surrounding areas were also subjected to radiation.  Therefore, free tissue 
transfer is often the most viable option.   
The transverse rectus abdominus myocutaneous (TRAM) flap is the primary 
choice for autogenous-tissue breast reconstruction and is performed as a free flap 
procedure [16].  Another common harvest area includes the latissimus dorsi flap and is 
commonly performed using the pendulum technique described above.  There is a 96% 
success rate for this type of reconstruction, making it one of the premier choices for 
reconstructive surgery [17]. 
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However, flap procedures have significant disadvantages and limitations as well.  
The procedure requires highly specialized microvascular-surgeons to reconnect all of the 
vasculature in the flap to maintain its viability after transplant.  Accordingly, this is also a 
very costly and time consuming procedure.  In the current era of managed care, expensive 
procedures are often targeted in cost-containment efforts.  Although microvascular tissue 
transfer procedures are costly, they are effective, which may ultimately decrease the cost 
of caring for these patients [18].  There is also significant scaring and donor site 
morbidity associated with the surgery, generally leaving a noticeable secondary tissue 
deficit to replace the tissue in the reconstructed site [14].  All together, these limitations 
are generally what cause patients to seek less invasive and less expensive alternatives 
such as implants, fillers, and fat grafting.   
Commercially Available Materials 
 
The most common reconstructive surgery method includes the use of 
commercially available natural and synthetic implants.  Natural implant materials include 
decelularized dermal tissues, such as Lifecell’s Alloderm™ product.  Synthetic materials 
are comprised mainly of silicones, mineral oils, and other various polymers.  Natural 
implants can be used on their own or in combination with synthetic implants depending 
on the state of the site to be reconstructed and preference of the surgeon.  More 
commonly, synthetic fillers are used alone to replace the volume of the deficit.  The 
advantage of using these materials as opposed to microvascular surgery is that there is no 
secondary surgery site for donor tissue.  To be a viable option, however, the tissue 
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surrounding the site of reconstruction must be healthy enough to accept the implant, 
which is often not the case for radiated tissues immediately following tumor resection.  
Additionally, synthetic materials only replace volume, not function and they are also 
associated with several side effects such as mechanical failure, volume loss over time, 
shifting over time, as well as fibrous capsular contraction.   
Fat grafting 
Fat grafting uses liposuction aspirate from one area of the body to fill deficits in 
another area of the body.  It is not a simple procedure and should be performed only by 
well-trained and skilled surgeons [2].  It has gained popularity in recent years as an 
alternative to flap grafting and implantable fillers because it has the capacity to replace 
volume and function using autologous tissue without extremely costly microsurgery or 
significant donor site morbidity issues.  There are three main components to fat grafting; 
tissue harvesting technique, storage, and graft volume maintenance.   
The first step in fat grafting is harvesting the fat tissue and preparing for transfer 
such that the graft will be sufficiently healthy to live and maintain graft site volume.  It is 
believed that liposuction results in up to 90% damaged cells [4].  However, these results 
vary greatly and are particularly sensitive to surgeon technique and available equipment.  
Additionally, it has been hypothesized that the failure of adipose grafts is largely the 
result of damage inflicted to the microvasculature during harvest [20].  It is believed that 
to help with these problems, vasoconstriction before extraction can help tissue maintain 
viability through reduced bleeding [21].  Though there are several recommendations by 
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various surgeons sharing aspects of their expertise this is still an area that requires 
optimization to help improve fat grafting as a reliable reconstructive technique.  
Once tissue is harvested, it can either be injected immediately or stored for 
additional injections.  It has been found that slow freezing of the tissue shortly after 
harvesting is an effective method of maintaining cell viability [21, 22].  It is 
recommended that cells be stored less than 6 months, although viable cells have been 
found in samples stored up to three years [21].  Storage of fat grafts allows for multiple 
grafting sessions with only a single harvest, reducing patient discomfort, cost, and time 
spent by both patient and physician [22].   
 The final step of fat grafting is injecting into the deficit.  The graft should be 
handled with gentle manipulation and placed in a vascular, tension-free recipient bed [1].  
Additionally, it is well known that fat transplanted into muscular or subcutaneous tissues 
survives well due to the rich blood supply compared to tissues such as the retroglandular 
plane where there is not much vasculature [1, 20].  This increases the chance of adipocyte 
survival and integration with the surrounding tissue.  The literature indicates that major 
complications associated with fat grafting are mainly attributed to technical errors and 
selection of the wrong anatomic site for both harvesting and injection of the fat [2].   
Results of fat grafting are highly dependent on surgeon technique and expertise.  
Additionally, there is a relative lack of information to guide physicians in choosing best 
practice techniques, selecting appropriate patients, and offering realistic advice on 
outcomes and potential complications [19].  For this reason, the ASPS Task Force 
developed an evidence-based review offering surgeons a graded summary of the 
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literature to help optimize the clinical use of fat grafts as currently practiced.  In 
summary, they found that though there is a great deal of variability in techniques and 
subsequent results, fat grafting can be considered a safe method of augmentation and 
correction of defects associated with various medical conditions.  In addition, the current 
trend in medicine is toward less aggressive methods compared to free tissue transfer 
reconstruction of complex wounds [16].  Therefore it is important to understand the 
components and limitations of fat grafting as practiced to make it more predictable and 
repeatable. 
 Though fat grafting is becoming more prevalent due to the advantages previously 
described, the main drawback is volume loss and consequently the requirement for 
multiple sessions to fill larger deficits.  The ASPS Task force review of human case study 
literature found that graft volume loss via reabsorption or necrosis is the primary cause of 
poor results. On average, there is a 40-60% reduction in graft volume using liposuction 
aspirate following transplantation, requiring surgeons to overfill and patients to sit 
through multiple grafting sessions over a period of several month [4].  Additionally, due 
to the high resorption, some surgeons have tried using excised intact fat pads as opposed 
to liposuction aspirate.  Several studies have demonstrated that the resorption rate was 
higher for aspirated fat compared with excised fat or harvested fat cylinders [1].  They 
proposed that to maintain adipocyte viability and subsequent graft survival, the capillary 
structure of the transplant should be preserved [1].  No matter the technique or type of fat 
grafted, currently there is no way to use this method on large deficits and obtain the 
desired result with just one procedure. 
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 Illouz et. al also described several case study results in breast reconstruction and 
cosmetic augmentations using autologous fat grafting.  They have practiced this 
procedure for over 25 years with predictable and satisfying results based on the condition 
that the treatment is performed in stages with small quantities of adipose tissue fat 
injected in each treatment session.  At each session, 25-180 cc of fat was grafted into 
each breast with the number of sessions ranging from one to five.  The total amount of fat 
transplanted in each breast ranged from 25-900 cc.  Though the results achieved in these 
case studies were quite natural in appearance and clients were very satisfied, volume 
limitations still exist, requiring multiple session treatments for desired results.   
It is widely accepted that patients who have underdone irradiation are not good 
candidates for breast alloplastic reconstruction because of the high rate of complications.  
Therefore, Salgerello et. al. described two case studies where patients post-radiation of 
the breast following breast cancer received two sessions of fat injections before implant 
placement to improve the compliance between implant and irradiated tissues.  They 
encourage autologous reconstruction alone or combined autologous and alloplastic 
reconstruction in irradiation patients because the autologous fat helps restore the local 
tissue from the radio-damage and allows for safer placement of the breast tissue 
expander/implant.   
In a post-radiation thigh defect case described by Jackson et. al., four grafting 
sessions were required to achieve a desired result.  The first session injected 80cc of fat 
harvested from the abdomen, 140cc at the second session, and 200cc during a third 
session at eight month intervals and a final injection of 140cc eleven months later.  
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Through this 30 month year period, significant improvement in the massive 
circumferential defect was made, though the results were still not to a completely natural 
state.  This ultimately showed, however, that viable fat cells can be transplanted and 
survive in adverse environments such as post-radiated tissues. 
Due to the significant advantages with using autologous fat transplantation, it 
appears to be the most favorable reconstructive option.  However, since current clinical 
defect reconstruction requirements are typically on the order of cubic centimeters, a more 
viable alternative to the multiple session treatments is required.  Therefore, a way to 
combine the benefits of fat grafting with a method of maintaining viability of constructs 
of significant dimensions would be of great clinical benefit. 
Adipose Tissue Engineering 
 To address the limitations of fat grafting, the field of adipose tissue engineering 
(ATE) has emerged.  This field endeavors to offer novel solutions and tissue engineering 
strategies to incorporate cell sources, biomaterial scaffolds, and a microenvironment to 
provide the appropriate cues and signals for growth and tissue formation [14].  To be 
successful for use in reconstructive applications, an adipose tissue construct must define 
and maintain a three-dimensional volume following implantation [23].  Additionally, the 
bioactivity of the regenerated adipose tissue needs to mimic that of native adipose tissue, 
not only in function, but in structure, which includes the incorporation of functional 
vasculature comprising blood vessels, nerves, and lymph supply [14].  Adipose tissue that 
both possesses active metabolic function and maintains volume after implantation would 
serve as a significant advancement over other reconstructive options. 
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One tissue engineering strategy for adipogenesis includes making use of 
transplanted, possibly tissue culture expanded, stem cells with high potential for 
proliferation and differentiation to achieve in vitro cell-induced regeneration.  An 
alternative strategy involves inducing in vivo formation of adipose tissue by making use 
of stem cells, like preadipocytes, already present in the body [8].  The following sections 
will describe the biology of adipose tissue, adipose derived stem-cells, vascularization, 
microenvironment, substrate materials, and the combination of these components for 
application in these adipose tissue engineering strategies as described in the literature. 
Biology of Adipose Tissue 
Adipose tissue is ubiquitous in the human body and is the most abundant tissue in 
the body [4].   The primary cellular component of adipose tissue is a collection of lipid 
filled cells known as adipocytes (Figure 10) that are held in place by collagen fibers.  
Other cellular components in adipose tissue include smooth muscle cells, endothelial 
cells, fibroblasts, blood cells, and preadipocytes [24].  Adipose tissue is highly vascular 
with each adipocyte attached to at least one capillary [4]. In fact, approximately 20% of 
the volume of native subcutaneous fat is vascular tissue [10].  Close interaction with the 




Figure 10:  Representation of adipocytes (fat cells). 
 Fat cells are fragile due to their structure and function, which must be considered 
when developing the methods for harvesting, storage, grafting, and use in tissue 
engineering applications.  The harvesting method must consider the large lipid content, 
which makes the cells easy to rupture, as well as the impact on the integrity of the 
vascular structure within the tissue.  Additionally, storage, treatment, and placement of 
the excised tissue, or graft, must also consider these characteristics of adipose tissue, 
particularly the requirement for immediate blood supply.   
 Adipose tissue also contains mesenchymal stem cells within the adult tissue, 
which are beneficial in tissue engineering applications.  It was once thought that bone 
marrow contained the largest proportion of these cells, but it has recently been discovered 
that adipose tissue contains up to 1000-fold more, 2% as compared to 0.002% in bone 
marrow [25].  Mesenchymal stem cells (MSCs) are interesting due to their ability to 
differentiate into adipose tissue, endothelial (blood vessels) and bone tissue (Figure 11).  
Additionally, adipose-derived mesenchymal stem cells are known to secrete angiogenic 
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and anti-apoptotic cytokines, growth factors, and extracellular matrix material that 
support tissue regeneration, enhance angiogenesis, and reduce tissue damage [4, 25]. 
 
Figure 11:  Differentiation Capability of Fat-derived Stem Cells.  
Ongoing research has the potential to answer questions about the optimal methods 
to work with adipose tissue, how to stimulate vascularization, how to induce adipose 
derived stem cells to differentiate into blood vessels, and many others to address the 
limitations of fat grafting.    
Vascularization 
 The application of adipose tissue grafting requires further research to engineer a 
clinically practical solution for large tissue deficits.  Currently, only small volumes fat-
grafts succeed because nutrients are supplied through simple diffusion due to the lack of 
an intact vascular network.  For this reason, large volumes are observed to necrotize, or 
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die, rather quickly after implantation due to the lack of vascular blood supply.  Diffusion 
can supply cells only over a distance of 150-200µm, insufficient for larger constructs [3].  
Vessels from the surrounding tissue grow into the transplanted tissue after a delay of 
several days, up to two weeks, and even then only nourish the periphery of the graft [3, 4, 
20].  By this time, up to 60% of the tissue is lost to necrosis.  To overcome this limitation, 
research must focus on accelerating vascularization.  Figure 12 is a depiction of vascular 
growth into a large volume fat graft.  It is this process that must be sped up to address 
volume loss currently associated with fat grafting. 
 
Figure 12:  Depiction of vascularization into graft (Adipose Transplant, Scaffold, etc.). 
Sufficient functional vasculature is vital for the construction of large constructs in 
which nutrients and oxygen diffusion is limited by distance and metabolic needs 
requiring immediate integration of vessels [14, 20].  Therefore, any potential clinically 
translatable tissue engineering modality must consider the microvasculature [1, 3, 4, 14, 
22, 24, 27].  Consequently, stimulation of vascularization is a growing area of research 
with much interest because of its essential role in tissue engineering.   
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There have been several studies evaluating co-transplanting endothelieal cells 
(EC), mesenchymal stem cells, or even partial vessel constructs along with adipose tissue 
[3, 20, 28].  Cotransplantation of autologous ECs to aid in the formation of a capillary 
network within the graft immediately after transplantation could result in a sufficient 
homogenous supply of the whole graft [3].  Other studies have evaluated the effect of 
growth factors and other hormones such as insulin on vascularization of new grafts [20]. 
The application or stimulation of endogenous growth factors may contribute to 
improvements in vascularization of transplanted fat because ischemic fat grafts 
themselves induce angiogenic cytokines [4, 20].  Additionally, the use of structural 
scaffolds seeded with stem cells to maintain volume and encourage faster vascularization 
has been an area of interest [27, 29].  Mechanical manipulation of vessels has also been 
evaluated along with the chemical and biochemical processes mentioned.  The evaluation 
of this wide array of mechanisms will contribute to the development of an optimal 
adipose tissue engineering process.  
Microenvironment 
The adipose niche comprised of adipogenic stimulants, growth factors, 
adipokines, and cytokines, makes up the complex microenvironment that stimulates and 
maintains native adipose tissue [14].  In addition to maintaining the vascular structure in 
the graft, there is evidence that the microenvironment of the recipient site can be 
manipulated to affect transplant success.  Many lines of evidence show that adipocyte 
precursor cells distribute widely in the connective tissues of the adult body and have high 
potential of adipogenesis and vascularization, depending on the microenvironment [27].  
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Manipulation of the microenvironment in not only the recipient site, but also the graft 
donor site, may be key to influencing faster vascularization such that larger volume grafts 
are clinically feasible. 
 In addition to preparation of the microenvironment of grafts and donor sites, some 
believe it may be possible to stimulate cells with a local environment such that it is 
suitable for their proliferation and differentiation, resulting in in vivo formation of 
adipose tissue without exogenous transplantation of cells [8, 27].  The manipulation of 
these factors in surrounding adipose tissue could stimulate the influx of adipose derived 
stem cells therefore increasing the likelihood of neovascularization and fat formation in 
the stimulated area. 
On the other hand, it is more prevalently believed that the true potential of 
adipose derived stem cells (ASC’s) will be achieved by using grafts enriched with these 
stem cells as a transplant to aid in formation of adipose tissue and neovascularization.  It 
is well known that mature transplanted adipocytes have already differentiated and 
provide little potential for further growth, so the only way to achieve potential for 
continued fat formation is to provide the environment with cells that have potential for 
differentiation and proliferation.  One study confirmed that enriched fat can survive better 
(35% on average) than non-enriched fat, and microvascularization can be detected more 
prominently especially in the outer layers of the fat transfer [2]. 
ASC’s are also much more resistant to mechanical damage and ischemic 
conditions than mature adipocytes making them even more ideal for optimizing fat 
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grafting methods [28].  Additionally, their introduction alone can impact the 
microenvironment by secreting cytokines that support tissue regeneration and minimize 
tissue damage [25].  Silvia et al. also found that MSC frequency positively correlates 
with blood vessel numbers supporting the belief that utilizing the potential of these stem 
cells will help address the issue of slow vascularization in fat grafts. 
Despite recognition of the potential for adipose derived stem cells there are still 
several concerns to address, including standardization of methods for procurement, cell 
isolation, identification, and cell culture [24].  Additionally, it is also believed that using 
undifferentiated MSCs in patients may be problematic because MSCs may undergo 
malignant transformation over time [10].  These concerns must be addressed to be a 
clinically applicable option for adipose tissue engineering. There would be great value in 
being able to stimulate in situ migration of ASCs to the site of a large tissue defect to 
encourage in vivo formation of new adipose tissue without the risks associated with 
extraction, expansion, and re-implantation. 
Scaffold Technologies 
 Synthetic and natural materials have been evaluated as scaffolds, or mechanically 
stable structures, to help fill large deficits.  These materials can be seeded with 
autologous adipose tissue, stem cells, or growth factors to provide an environment for 
cells to migrate, expand, and form soft tissue.  The scaffold plays two important roles in 
tissue regeneration: it provides a platform for cells to attach and maintain life as well as 
provides space for tissue regeneration [8].  Therefore, the material of the scaffold must 
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meet both aesthetic requirements while also providing surfaces that will promote cellular 
attachment throughout the volume of the structure. 
Several biocompatible synthetic polymers have been molded into various shapes 
and sizes and seeded with liposuction aspirate, stem cells, endothelial cells, and even 
intact microvessel constructs [3, 14, 28, 29].  The most common polymers are used in 
many tissue engineering areas of research and applications, so their properties, 
degradation products, and biocompatibility are fairly well understood.  Additionally, 
tailoring their exact composition enables the manipulation of the resulting mechanical 
properties and longevity.  Table 4 outlines the strengths and weaknesses of the most 
common synthetic polymers used in adipose tissue engineering applications.  The base 
polymers can be mixed together and/or incorporate chemical or surface modifications in 
an effort to modulate the mechanical properties and increase cellular and implant 
biocompatibility [24].  There have been various results observed regarding longevity of 
cell seeded scaffolds using these materials, but overall, there have been no clinically 
translatable constructs produced using these methods to date.     
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Synthetic Polymer Strengths Weaknesses 
Poly(lactic acid) Supports adipogenesis in vivo  
    and in vivo 
Degrade in vivo after 12 weeks 
Poly(glycolic acid) Supports adipogenesis in vivo  
    and in vivo 
Degrade in vivo after 4 weeks 
Poly(lactiv-co-glycoloic acid) Supports adipogenesis; induces  
    vascularization in vivo 
Long-term adipose tissue engineering  
    studies have not been performed   
    in vitro or in vivo 
Poly(ethlene glycol) Supports adipogenesis; maintains  
    shape afer in vivo culture 
In vivo degradation rate not well  
    characterized 
Fluoropolymers Maintains shape Nondegradable; unfavorable surface  
    for cell adhesion 
Silicones Biocompatible Nondegradable   
Table 4:  Common Synthetic Polymers Used for Adipose Tissue Engineering.  
Adapted from [14]. 
  
Similar studies have been conducted using natural polymers [10, 28].  Table 5 
provides a list of examples and describes the strengths and weaknesses of these materials 
for adipose tissue engineering applications.  These materials are thought to provide a 
more natural, biocompatible environment to seed stem cells, therefore, resulting in better 
outcomes. For example, a study using micronized decellularized (DCM) dermal matrix, 
in conjunction with ASC’s, found that two months following implantation, the graft 
contained many large capillaries while injected micronized DCM alone only contained 
some fibroblast-like cells and a few small capillaries [28].  Additionally, DCM materials 
are also known to contain growth factors with strong angiogenic activity and the ability to 
promote preadipocyte growth [8]. 
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Material Strengths Weaknesses 
Adipose-derived ECM Native ECM promotes favorable  
   microenvironment for 
adipogenesis 
Has not yet been formulated as a  
   3D porous scaffold 
Collagen Prevalent in native adipose ECM; 
   promotes favorable adipose 
   outcomes; well characterized 
Fast degradation rate in vivo 
Decellularized human   
   Placenta 
Allogenic approach to generate  
   large adipose substitutes;  
   supports adipose tissue formation 
Extensive isolation and 
decellularization 
   procedure (18 days) 
Fibrin Biocompatible material that can  
   support adipogenesis in vivo 
Has not yet been formulated as a  
   3D porous scaffold 
Gelatin Supports adipogenesis in vivo; 
   retains shape after culture 
Primarily used as material for  
   microspheres; 3D construct for 
   adipose tissue engineering not  
   well utilized 
Hyaluronan Favorable mechanical properties; 
   supports adipose tissue formation 
3D porous scaffolds have not been 
   widely successful for adipose 
   outcomes 
Matrigel Supports adipogenesis   Cannot be used in human in vivo 
   applications 
Silk Supports adipogenesis; favorable 
   mechanical properties;  
   slow degradation rate 
Have not been utilized for long-
term 
   in vivo soft tissue engineering  
   (>6 months) 
Table 5:  Common Natural Materials Used for Adipose Tissue Engineering.  
Adapted from [14]. 
 
There have also been several promising studies using intact placental decellular 
matrix due to its structural integrity, biocompatibility, and inclusion of growth factors 
[14, 23, 24].  In one study, the implant volume appeared to be maintained and contained 
an extensive number of mature adipocytes at 8 weeks [23].  The preservation of the 
implant volume is thought to be related to the complex extracellular matrix architecture 
of this intact decellularized tissue. 
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In addition to seeding scaffolds with ASC’s, several other studies have evaluated 
the inclusion of autologous endothelial cells as well as intact engineered mircrovessels to 
address the immediate need for vascularization of this large tissue construct.  It is thought 
that by providing these components, the developing capillary network may form 
connections more immediately to vessels sprouting in from the surrounding tissue, 
supplying blood to the periphery but most importantly in the graft’s center [3].  
Summary 
A schematic provided by Charles Patrick (Figure 13) depicts an idealized scenario 
for adipose tissue engineering incorporating all of the components previously discussed, 
including the use of autologous adipose tissue, potentially enriched with ASC’s, in 
conjunction with scaffold materials and manipulation of the microenvironment using 
endotheilial cells, microvessels and potentially growth factors.  The key is finding the 
right combination of these components, externally introduced or internally induced, for 
the specific applications that will lead to a clinically practical solution for reconstructive 










Leading Companies & Products in Reconstructive Surgery 
There are several types of breast and other anatomy-specific cosmetic implants 
(i.e. chin, lips, buttocks, etc.) currently on the market.  However, this section will focus 
on the companies that are producing general soft tissue constructs that can be used for the 
non-specific deformities discussed in the earlier sections, including tumor resections and 
congenital defects, as opposed to purely cosmetic augmentation.  Table 6 lists the most 
common filler materials used in place of adipose tissue in reconstructive surgery.   
In addition to filler materials listed in table 6, surgical meshes are common 
product used for reconstructive surgery to reinforce soft tissues where weaknesses exist.  
There are over 450 devices listed as surgical meshes on the FDA 510K database.  These 
devices support defect repair generally without filling deficits and augmenting the 
appearance of the area.  Some of the leaders in this industry are Atrium Medical 
Corporation, Boston Scientific, Cook Medical Inc., Ethicon Inc., Synovis Life 
Technologies, Inc., and Serica Technologies.  Though these companies are not currently 
in the market with adipose tissue alternative reconstructive filler products, they are large 
companies with adjunctive products in the market.  Therefore, there is incentive for them 
to address the unmet needs in their market by evaluating the potentials in adipose tissue 




Material Product (Manufacturer) Primary Component(s) 
Extracellular Matrix/ 
Tissue Matrix AlloDerm (LifeCell Corp) Decellularized human dermal tissue 
 
Autologen (Collagenesis, Inc.) Autologous human dermal collagen 
 
Cymetra (LifeCell Corp) Micronized AlloDerm 
 
PriMatrix (TEI Biosciences) Fetal bovine decellularized matrix 
 
Dermalogen (Collagenesis, Inc.) Allogenous human dermal tissue matrix 
 
Fibrel (Mentor Corp) Fibrin Gel 
 
Prevelle® Silk (Mentor Corp) Hyaluronic acid-based dermal filler 
 
Hylaform (Biomatrix Corp) Hyaluonic acid gel 
 
Restylan (Q-Med) Viscoelastic hylan gel 
 
Zyderm I (Collagen Aesthetics) Bovine dermal collagen (35 mg/mL) 
 
Zyderm II (Collagen Aesthetics) Bovine dermal collagen (65 mg/mL) 
 
Zyplast (Collagen Aesthetics) Zyderm II with gluteraldehyde 
    Synthetic Polymers 
                           Artecoll (Rofil Medical Inc) Polymethylmethacrylate microspheres 
 
Bioplastique (Bioplasty, Inc.) Cross-linked polydimethylsiloxane 
 
Gortex (W.L. Gore & Associates) Expanded polytetrafluoroethylen (ePTFE) 
 
Marlex (Davol, Inc.) Porous/mesh-form polyethylene 
 
Softform (Collagen Aesthetics) Expanded polytetrafluoroethylen (ePTFE) 
       Silicone Various Formulas (Dow Corning)  
Table 6:  Materials used in place of adipose tissue in reconstructive surgery.  




Up-and-coming Companies with Adipose Technologies 
Cytori Therapuetics is the most publicized company with products addressing 
needs in the current fat grafting market with its Cellution technologies that have potential 
application in adipose tissue engineering strategies.  Cytori’s products are marketed as 
revolutionary technologies for harvesting, filtering, and transferring fat grafts.  These 
technologies address some of the issues with cell viability of the liposuction aspirate by 
purifying it before transplantation. They are also currently working with Olympus 
Corporation to develop a next generation device to extract and concentrate adipose-
derived stem and regenerative cells with larger tissue processing volume 
(www.cytori.com).  Table 7 lists Cytori’s FDA cleared products. 
Device 510K Intended Use 
AFT System  Aspiration, harvesting, filtering, and transferring autologous tissue 
Celution Cell Concentration Device 
Collection, Concentration, washing, and reinfusion 
of autologous cells to obtain concentrated blood 
cells for reinfusion 
PureGraft 250-PURE System   Harvesting, filtering, and transferring autologous fat tissue for aesthetic contouring 
Table 7: Cytori Therapeutic FDA approved devices for use in fat grafting and tissue 
engineering applications (www.fda.gov). 
 
AestheTec is a start-up company that is reported to be developing fat grafting 
technologies.  However, there are no approved or marketed products by this company and 
there is very little information available at this time describing the specific technologies 
on which they are working [19].   
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Other ATE Applicable Technologies 
CryoLife has two marketed technologies that are or could be applicable to future 
adipose tissue engineering strategies.  Their cryopreserved vascular conduit alternative 
products (including main arteries and veins) could be used to introduce immediate 
vascularity into engineered grafts.  Additionally, they have a patented decellularization 
process in the area of cardiovascular implants.  However, this type of process has wider 
applicability across other tissues as well, including potential soft tissue constructs similar 
to LifeCell technologies described above. 
NOVADAQ is a company that focuses on plastic and reconstructive surgery 
imaging technologies.  They offer the SPY Imaging System that produces real-time 
visual images of blood vessels in minutes.  This tool could not only be used to assess 
blood flow in soft tissue grafts, engineered or flap graft surgeries, but could also 
potentially be used as a sophisticated research tool to assess up-and-coming adipose 
tissue engineering technologies for their successful vascularization over time in animal 
models and clinical trials.  An example software image showcasing the capability of this 









Due to unmet needs in the reconstructive market, including difficult 
reconstructive cases that currently have limited options and improvement of functional 
and cosmetic outcomes for other reconstructive cases, much research has been performed 
to help develop an adipose tissue based clinically practical solution.  From a review of the 
literature and current technologies, it is evident that there are several technology 
opportunities that could lead to products to help address these unmet needs.  The main 
objective of creating a single stage adipose graft treatment may be a long-term 
technology goal; however, there are several opportunities to take advantage of by 
combining current research with state-of-the art technologies already utilized in other 
applications.  The main areas of focus for product technologies are as follows: 
 Harvest Adipose Tissue 
 Devices, methods and/or additives to minimize graft cell damage 
 Devices and/or methods to improve isolation and/or expansion of stem 
cells 
 Devices and/or methods to maintain capillary structure of graft 
 Improve/Speed up Vascularization 
 Prepare graft site to accept graft – increase surrounding vascularization 
and create space to accept graft sub-dermally 
 Stimulate micro-environments to influence in vivo stem cell differentiation 
 Create micro-mechanical changes to influence angiogenesis 
 Maintain Volume During Graft Integration 
 Use of Decellularized Large Tissue Scaffolds 
 Prevent necrosis/apoptosis 
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VALUE PROPOSITION  
Economical, clinically-adopted solutions equal revenue potential for businesses.  
To companies not currently in the market, but adjacent to it, the reconstructive and 
cosmetic markets are attractive and actively growing.  Therefore, there is value for both 
the potential customers as well as businesses to evaluate technology opportunities that 
may help to address the increased need for better/safer cosmetic & functional outcomes 
as an alternative to: 
 Implants:  considered “good enough,” but are prone to several side-effects, 
mainly because they are not autologous tissue. 
 Flap grafting:  requires microvascular surgery which is an expensive and time-
intensive surgery with a high risk of donor-site morbidity. 
 Fat-grafting:  requires multiple sessions over a long period of time to achieve 
acceptable results. 
New technologies should provide: 
Value to the Customer (Patients & Physicians) 
 Decreased Cost (as compared to flap grafting) 
 Improved Functional & Cosmetic Results 
 Single Procedure 
 Reduced Side Effects 
46 
 
Value to the Business 
 Strategic Expansion Opportunity (Increase Market Share) 
 Leverage Existing Technologies in New Application 





 Tissue engineering research programs are expensive, as well as time and 
personnel resource intensive.  Therefore, strategic decision analysis should be completed 
to evaluate the business appetite for potentially long-term and high risk research before 
beginning an adipose tissue engineering program.  It is recommended that a detailed 
business plan addressing a specific market segment (i.e. breast lumpectomy 
reconstruction) should be completed to help narrow the areas of research and application 
of resulting technologies.  Furthermore, ideally, if a program is initiated to review 
technologies in this area, it is recommended that the short-term opportunities, especially 
adjunctive therapies to fat-grafting, be evaluated in parallel to some of the longer-term 
technology opportunities to help balance the program and ensure its longevity by creating 
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